Abstract
Neuraminidase of the influenza virus is the target of the antibiotic drugs peramivir, oseltamivir and zanamivir. The WHO Collaborating Centre in China announced these drugs (peramivir, oseltamivir and zanamivir) to be effective to treat the 2013 H7N9 influenza virus. Herein, we report the findings of molecular simulations and computational alanine-scanning mutagenesis for peramivir, oseltamivir and zanamivir with the neuraminidase of 2013 H7N9 influenza. Our simulation results theoretically suggest that peramivir might be the best potential antiviral agent for treatment of avian influenza A (H7N9); the Asp147 and Arg367 residues are responsible for the H7N9 neuraminidase of the 2013 influenza drug selectivity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
